DDX3X
Relevance tier by entity
| Entity | Tier | Description |
|---|---|---|
| BL | 1-a | aSHM target and high-confidence BL gene |
| DLBCL | 1-a | aSHM target and high-confidence DLBCL gene |
| FL | 2-a | aSHM target; Although recurrent, the relevance of mutations in FL is tenuous |
Mutation incidence in large patient cohorts (GAMBL reanalysis)
| Entity | source | frequency (%) |
|---|---|---|
| BL | GAMBL genomes+capture | 44.34 |
| BL | Thomas cohort | 48.70 |
| BL | Panea cohort | 39.60 |
| DLBCL | GAMBL genomes | 8.80 |
| DLBCL | Schmitz cohort | 4.68 |
| DLBCL | Reddy cohort | 4.50 |
| DLBCL | Chapuy cohort | 5.56 |
| FL | GAMBL genomes | 2.54 |
Mutation pattern and selective pressure estimates
| Entity | aSHM | Significant selection | dN/dS (missense) | dN/dS (nonsense) |
|---|---|---|---|---|
| BL | Yes | Yes | 19.270 | 125.826 |
| DLBCL | Yes | No | 3.193 | 8.744 |
| FL | Yes | No | 11.136 | 21.489 |
aSHM regions
| chr_name | hg19_start | hg19_end | region | regulatory_comment |
|---|---|---|---|---|
| chrX | 42800580 | 42804184 | intergenic | NA |
[!NOTE] First described in BL in 2012 by Schmitz R. First described in DLBCL in 2018 by Schmitz R. First described in FL in 2023 by Dreval K
View coding variants in ProteinPaint hg19 or hg38
View all variants in GenomePaint hg19 or hg38
Citing
If you use the information or data from this site, please cite
Krysta Coyle, Kostiantyn Dreval, Daniel Hodson and Ryan D. Morin. Audit of B-cell cancer genes. Blood Adv (2025) 9 (8): 2019–2031.
Disclaimer
The content in these pages has been populated, in part, by an automated process. Although we have scrutinized every page to ensure accuracy, errors will inevitably exist. If you find an error please report it as an issue and we will address it.
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
Adapt — remix, transform, and build upon the material for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms.